In this randomized, open-label trial, the number of externally verified TB diagnoses was higher among patients who received empiric TB treatment vs those who received only isoniazid preventive therapy at ART initiation.
During a 10-year period, immediate ART was associated with a 93% reduction in the risk of HIV transmission between serodiscordant couples when compared with initiating ART after CD4+ cell counts dropped to 250.
Suboptimal adherence to required doses reduced with daily, time-driven, and event-driven dosing strategies, suggesting additional interventions needed to optimize PrEP adherence in this population.
Although daily PrEP was associated with higher adherence and drug concentrations than were time-driven and event-driven PrEP, time-driven PrEP was associated with high drug coverage and required fewer doses.
In this Canadian retrospective analysis, no cases of mother-to-child HIV transmission occurred among 18 women who received raltegravir during pregnancy because of concerns regarding risk of vertical transmission (drug resistance, detectable HIV-1 RNA, late ART initiation).
Higher SVR12 rates were observed regardless of previous HCV treatment experience or presence of cirrhosis; lower response rates observed in black vs nonblack patients.
SVR12 rates with grazoprevir/elbasvir in HCV/HIV-coinfected patients comparable to those of HCV-monoinfected patients with no impact on HIV disease or serious treatment-related adverse events.
Adherence was relatively high but varies according to study site and participant race; HIV-1 incidence rate was low at 0.43/100 person-years.
Black MSM had the lowest adherence levels across the study and a sharp drop off in adherence occurred among all participants between Week 12 and Week 24, corresponding to a reduced frequency of study visits beginning at Week 12.